| Sku |
AAP53631 |
| Old sku |
AAPP30801 |
| Price |
$99.00 |
| Name |
NUP98 Peptide (AAP53631) |
| Purchase info |
To purchase this peptide:
- Copy peptide sku
- Click on this link
- Paste into field "Peptide Sku"
|
| Size |
100 ug |
| Gene |
NUP98 |
| Alias symbols |
ADIR2, NUP196, NUP96 |
| Gene id |
4928 |
| Description of target |
The nuclear pore complex (NPC) is comprised of approximately 50 unique proteins collectively known as nucleoporins. The 98 kD nucleoporin is localized to the nucleoplasmic side of the NPC. Rat studies show that the 98 kD nucleoporin functions as one of several docking site nucleoporins of transport substrates. The human gene has been shown to fuse to several genes following chromsome translocatons in acute myelogenous leukemia (AML) and T-cell acute lymphocytic leukemia (T-ALL). This gene is one of several genes located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. Signal-mediated nuclear import and export proceed through the nuclear pore complex (NPC), which is comprised of approximately 50 unique proteins collectively known as nucleoporins. The 98 kD nucleoporin is generated through a biogenesis pathway that involves synthesis and proteolytic cleavage of a 186 kD precursor protein. This cleavage results in the 98 kD nucleoporin as well as a 96 kD nucleoporin, both of which are localized to the nucleoplasmic side of the NPC. Rat studies show that the 98 kD nucleoporin functions as one of several docking site nucleoporins of transport substrates. The human gene has been shown to fuse to several genes following chromsome translocatons in acute myelogenous leukemia (AML) and T-cell acute lymphocytic leukemia (T-ALL). This gene is one of several genes located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. Alternative splicing of this gene results in several transcript variants; however, not all variants have been fully described. |
| Swissprot id |
A8KA17 |
| Protein accession num |
NP_005378 |
| Nucleotide accession num |
NM_005387 |
| Protein size |
937 amino acids |
| Molecular weight |
98kDa |
| Application |
WB |
| Partner proteins |
CREBBP,EP300,IPO5,KPNB1,NUP133,NUP62,NUP88,NUP98,NXF1,RAE1,RCC1,SEC13,TNPO1,TPR,CREBBP,CRM1,EP300,KAP104,KPNB1,MOBKL1B,NFX1,NPM1,NUP133,NUP88,NXF1,PARP11,QRICH2,RAE1,Rae1,TNPO1,TNPO2,TPR,USP7 |
| Quality control |
The peptide is characterized by mass spectroscopy |
| Key reference |
Pan,Q., (2008) Oncogene 27 (24), 3414-3423 |
| Description |
This is a synthetic peptide designed for use in combination with anti-NUP98 antibody (Catalog #: ARP53631_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details. |
| Product format |
Lyophilized powder |
| Reconstitution and storage |
Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20C. Avoid repeat freeze-thaw cycles. |
| Lead time |
Domestic: within 24 hours delivery International: 3-5 business days |
| Protocol |
|
| Tips |
See our General FAQ page. |
| Availability |
In Stock |
